Nanologica Ab · OMXSTO:NICA
Nanologica Ab — Q2 2025 Earnings Presentation
26 slides from Nanologica Ab's earnings presentation, Jul 10, 2025
Slide 1: Interim Report Q2 2025
INTERIM REPORT Q2 2025 N A N O LO G I C A A B ( PU B L )
Slide 2: Financial Summary
FINANCIAL SUMMARY • Net sales for the second quarter amounted to SEK 2,335 thousand (2,174) and for the first half of the year to SEK 13,087 thousand (7,211) • Operating loss for the quarter amounted to SEK -10,763 thousand (-9,832) and for the half-year to SEK -20,004 thousand (-25,163) • Loss befo
Slide 3: CEO Comment
CEO COMMENT As expected, the second quarter was not as strong in terms of sales as the first. However, we are making clear progress in our work to streamline the production process, which will generate positive effects over time. We also received our first order from the US for testing NLAB Saga® on
Slide 4: CEO Comment (continued)
and this has the potential to be a valuable addition to the revenues for the company. The second project is NLAB® Idun, a non-silica-based purification media that is a complement to NLAB Saga® in the purification of peptide-based drugs. By complementing our offering with NLAB® Idun, we will be able
Slide 5: This is Nanologica
THIS IS NANOLOGICA Better and cheaper medicine to a larger number of patients Nanologica is a Swedish life science tools company that develops, manufactures and sells advanced input goods to pharmaceutical manufacturing companies. With a foundation in materials science and nanotechnology, we have de
Slide 6: Five Reasons to Invest in Nanologica
FIVE REASONS TO INVEST IN NANOLOGICA By developing chromatography products that enable pharmaceutical manufacturers to streamline their production and lower their production costs, Nanologica not only strives to create value for its shareholders, but also to contribute to more patients across the wo
Slide 7: Operating Income and Result
OPERATING INCOME AND RESULT the finished goods inventory corresponded to SEK Net sales for the second quarter amounted to SEK 22,560 thousand compared to SEK 28,807 2,335 thousand (2,174), of which preparative thousand at the beginning of the year. The chromatography amounted to SEK 1,844 thousand f
Slide 8: Fluctuations in Revenue Generation; Employees and Organization
ongoing and planned production improvements Warrants of series TO5 have an impact in the form of increased TO5 was issued as part of each unit in the unit production volumes. To account for possible issue resolved in August 2024. Each warrant of delays in the ongoing implementation of series TO5 ent
Slide 9: Annual General Meeting, Financial Calendar, Future Prospects
The board of directors is of the opinion that the FINANCIAL CALENDAR offer does not reflect the long-term potential or Interim Report Q3 2025 October 23, 2025 underlying value of Nanologica. The board of Year-End Report 2025 February 12, 2026 directors therefore unanimously recommends the Annual Rep
Slide 10: External Factors, Auditors Review, Assurance
materials and inputs, and currency fluctuations. A since none have production in the US. detailed description of risk exposure and risk management can be found in Nanologica's Annual The company's current loans run at fixed interest Report for 2024 on pages 51–54. rates, which means that the costs f
Slide 11: Financial Reports and Notes
FINANCIAL REPORTS AND NOTES
Slide 12: Consolidated Income Statement
CONSOLIDATED INCOME STATEMENT 2025 2024 2025 2024 2024 Amounts in TSEK Apr - Jun Apr - Jun Jan - Jun Jan - Jun Jan - Dec Net sales 2 335 2 174 13 087 7 211 14 538 Change in inventories, finished goods 816 12 899 -2 761 14 960 18 163 Other operating income -175 32 -101 57 633 Operating expenses Raw m
Slide 13: Consolidated Balance Sheet
CONSOLIDATED BALANCE SHEET 2025 2024 2024 Amounts in TSEK Jun 30 Jun 30 Dec 31 ASSETS Fixed assets Intangible fixed assets Capitalized expenditure for research and development and similar 12 479 18 492 15 234 Concessions, patents, licenses, trademarks and similar rights 0 1 486 0 Tangible fixed asse
Slide 14: Consolidated Statement of Changes in Equity
CONSOLIDATED STATEMENT OF CHANGES IN EQUITY 2025 2024 2025 2024 2024 Amounts in TSEK Apr - Jun Apr - Jun Jan - Jun Jan - Jun Jan - Dec Total equity at the beginning of the period 63 940 11 075 74 112 -1 898 -1 898 0 Profit/loss for the period -12 312 -11 126 -22 483 -27 895 -65 629 Other comprehensi
Slide 15: Consolidated Cash Flow Statement
CONSOLIDATED CASH FLOW STATEMENT 2025 2024 2025 2024 2024 Amounts in TSEK Apr - Jun Apr - Jun Jan - Jun Jan - Jun Jan - Dec Operating activities Operating profit/loss -10 784 -9 832 -20 025 -25 163 -59 255 Adjustment for items not affecting cash flow 3 091 2 882 6 734 6 543 15 359 Valuation of other
Slide 16: Notes
NOTES NOTE 1 GENERAL INFORMATION This report covers the Swedish parent company Nanologica AB (publ), corporate registration number 556664- 5023, and its subsidiaries. The parent company is a limited liability company with its registered office in Stockholm, Sweden. The address of the main office is
Slide 17: Composition of Net Sales
Composition of net sales, per product 2025 2024 2025 2024 2024 type (TSEK) Apr - Jun Apr - Jun Jan - Jun Jan - Jun Jan - dec Preparative chromatography 1 844 2 069 11 948 6 881 12 727 Analytical chromatography 491 105 1 139 330 808 Application development and similar services 0 0 0 0 1 003 Total 2 3
Slide 18: Note 7 Items Not Affecting Cash Flow
NOTE 7 ITEMS NOT AFFECTING CASH FLOW 2025 2024 2025 2024 2024 Amounts in TSEK, group Apr - Jun Apr - Jun Jan - Jun Jan - Jun Jan - Dec Depreciations 3 180 3 075 6 822 6 728 14 119 Write-downs/disposals of intangible assets 0 0 0 0 1 426 Write-downs/disposals of fixed assets 0 0 0 0 3 Other items -89
Slide 19: Definitions of Alternative Performance Measures
always comparable to measures used by other companies. These financial measures should therefore not be seen as a substitute for measures defined under IFRS. Reported key figures are defined according to IFRS unless otherwise stated. ESMA's guidelines on alternative performance measures are applied,
Slide 20: Group Quarterly Data
2025 2024 2024 Jun 30 Jun 30 Dec 31 A. Equity according to the balance sheet (TSEK) 51 594 14 455 74 112 B. Total assets according to balance sheet (TSEK) 112 608 106 218 143 099 A/B = Equity/assets ratio (%) 46 14 52 A. Equity according to the balance sheet (TSEK) 51 594 14 455 74 112 B. Number of
Slide 21: Income Statement for the Parent Company
INCOME STATEMENT FOR THE PARENT COMPANY 2025 2024 2025 2024 2024 Amounts in TSEK Apr - Jun Apr - Jun Jan - Jun Jan - Jun Jan - Dec Net sales 2 335 2 174 13 087 7 211 14 538 Change in inventories, finished goods 816 12 899 -2 761 14 960 18 163 Other operating income -175 32 -101 57 633 Operating expe
Slide 22: Balance Sheet for the Parent Company
BALANCE SHEET FOR THE PARENT COMPANY 2025 2024 2024 Amounts in TSEK Jun 30 30 Jun Dec 31 ASSETS Fixed assets Intangible assets Capitalized expenditure for research and development and similar 11 801 21 986 16 642 Concessions, patents, licenses, trademarks and similar rights 0 1 486 0 Total intangibl
Slide 23: Balance Sheet for the Parent Company
BALANCE SHEET FOR THE PARENT COMPANY 2025 2024 2024 Amounts in TSEK Jun 30 30 Jun Dec 31 EQUITY AND LIABILITIES Equity Share capital 4 507 14 821 8 836 Fund for development expenditure 120 484 281 Total restricted equity 4 627 4 902 9 117 Non-restricted equity Share premium reserve 442 115 350 351 4
Slide 24: Statement of Changes in Equity for the Parent Company
STATEMENT OF CHANGES IN EQUITY FOR THE PARENT COMPANY 2025 2024 2025 2024 2024 Amounts in TSEK Apr - Jun Apr - Jun Jan - Jun Jan - Jun Jan - Dec Total equity at the beginning of the period 58 356 5 898 68 641 -6 940 -6 940 Share capital 1 0 1 0 -10 403 Non registered share capital 0 -12 208 0 -10 40
Slide 25: Cash Flow Statement for the Parent Company
CASH FLOW STATEMENT FOR THE PARENT COMPANY 2025 2024 2025 2024 2024 Amounts in TSEK Apr -Jun Apr - Jun Jan - Jun Jan - Jun Jan - Dec Operating activities Operating profit/loss -10 913 -9 881 -20 299 -25 409 -59 768 Adjustment for items not affecting cash flow 2 286 3 042 5 137 6 104 13 372 Write-dow
Slide 26: Nanologica AB (publ)
Nanologica AB (publ) Forskargatan 20 G, SE-151 36 Södertälje, Sweden Ph: 08-410 749 49 www.nanologica.com